Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.35 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431744 | 0.88 | KMT2A (0.36) | ALDH1A1OPRM1OPRD1 | |
| SCHEMBL4880934 | 0.81 | UTS2R (0.38) | ALDH1A1 | |
| SCHEMBL4440061 | 0.75 | MAPK1 (0.36) | LMNATSHR | |
| SCHEMBL4432781 | 0.75 | NPFFR1 (0.36) | ALDH1A1OPRD1LMNA | |
| SCHEMBL1554091 | 0.75 | CHRM1 (0.49) | ADRA1AKCNH2CHRM5CHRM3ADRA1B | |
| SCHEMBL4430180 | 0.75 | UTS2R (0.43) | — | |
| SCHEMBL15808512 | 0.74 | EPHX2 (0.37) | ALDH1A1TSHR | |
| SCHEMBL4434641 | 0.74 | USP2 (0.39) | ALDH1A1LMNATSHR | |
| SCHEMBL4432724 | 0.72 | UTS2R (0.61) | LMNA | |
| SCHEMBL4428992 | 0.72 | UTS2R (0.42) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | claimed |
| EP-2049120-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2009-04-22 | — | — | EP | claimed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | claimed |
| WO-2008016534-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039454-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, NTSR2 | ALDH1A1 4139/4885OPRL1 102/4885OPRM1 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.